Skip to main content
. 2022 Jun 21;2022(6):CD006404. doi: 10.1002/14651858.CD006404.pub4

3.6. Analysis.

3.6

Comparison 3: Pyronaridine‐artesunate versus mefloquine plus artesunate, Outcome 6: Adverse events leading to withdrawal